anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a carnitine derivative having a weak side effect and an excellent neutral-fat reducing effect, an excellent anti-obesity drug having a weak side effect, a food preparation, and a cosmetic, each comprising the derivative.  <P>SOLUTION: The carnitine derivative is a derivative comprising carnitine and a fatty acid. The derivative is obtained by alkaline reduction of a fermented product prepared by fermenting an admixture of an edible fish, crushed soybeans, and yeast. The anti-obesity drug comprises the carnitine derivative having a neutral-fat reducing effect as an essential ingredient. The food preparation is comprised of a composition comprising 0.01 to 0.1 part by weight of an extract of Banaba leaves and 0.03 to 3 parts by weight of an extract of green tea leaves relative to 1 part by weight of the carnitine derivative. The cosmetics is a cosmetic having a cellulite reducing effect which is comprised of a composition comprising 0.03 to 3 parts by weight of an extract of persimmon leaves relative to 1 part by weight of the carnitine derivative.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PURPOSE: A composition containing miRNA for controlling pigmentation gene expression is provided to suppress tyrosinase, tyrosinase-related proteins, and melan-A expression. CONSTITUTION: A composition for controlling pigmentation gene expression contains miRNA containing a base of sequence number 1 as an active ingredient. The miRNA has continuous 27 bases containing ccuucuu of sequence number 1 and a base which suppresses pigmentation gene expression. The pigmentation gene is tyrosinase, tyrosinase-related protein 1, or melan-A gene. The miRNA targets 909-915th nucleic acids of melan A mRNA 3'-UTR. The composition is a cosmetic or pharmaceutical composition for skin whitening. A composition for controlling pigmentation gene expression contains a complementary base with miRNA of sequence number 1. [Reference numerals] (AA) Relative TYR/GAPDH mRNA expression level; (BB) Comparative embodiment 1; (CC) Comparative embodiment 2; (DD) Embodiment 1
There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with sham tDCS and cognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
The invention relates to a Chinese traditional medicine combination for treating alcoholic fatty liver, the extraction process, the preparation process, the function and treatment and the adaptation disease. The medicine combination is prepared by Herba Artemisiae Scopariae, Polyporus, Rhizoma Atractylodis Macrocephalae, Ramulus Cinnamomi, Radix Puerariae, Rhizoma Alismatis and Rhizoma Dioscoreae Nipponicae in a certain weight proportion. According to the property of the effective ingredient in each drug, the invention is characterized in that the medicine is prepared respectively by the process methods, ethanol inverse flow extraction, water extraction and alcohol precipitation of the extractive; thereby the efficacy components are maintained to the utmost extent. The Chinese traditional medicine combination has the effects of clearing liver and benefiting dampness, dredging channels and removing stasis. The invention is mainly applicable for treating alcoholic fatty liver (stagnancy of damp-heat, blocked liver channels) which shows the symptoms of flank ribs expansion and smothering or pain, bitter taste and repulsive vomit, abdominal distension, difficult bowels movement or astriction, yellow urine, greasy and slightly yellow tongue coating, and thready and slippery pulse. The invention has the advantages of prescription basing on the Chinese traditional medicine theory, simple process, and quick and reliable effect.
Receive two doses of alemtuzumab (Campath-1H, 30mg) by intravenous (IV) infusion. One dose during kidney transplant surgery and the second dose on day 2 (post-surgery) to achieve peripheral T-cell depletion. IV glucocorticoids will be given prior to Campath administration to limit cytokine release syndrome in association with this monoclonal antibody. MMF on the day of surgery and continue taking it by mouth, twice daily. TAC started on the 1st day after surgery, and then taken by mouth twice daily.
Furmonertinib (AST2818) 80mg QD. All patients enrolled into this group will receive furmonertinib 80mg daily.
Participants who have a blockage in their tear drainage system on probing and irrigation. Participants will have received a drop of Proparacaine Hydrocholoride 0.5% ophthalmic solution in one eye and a drop of BSS in the other eye prior to probing and irrigation.
Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate. It has a molecular weight of 418.5 and a molecular formula of C21H26N2O7. The structural formula is:

Nimodipine is a yellow crystalline substance, practically insoluble in water.

Nimodipine capsules are formulated as soft gelatin capsules for oral administration. Each liquid filled capsule contains 30 mg of nimodipine in a vehicle of glycerin, peppermint oil and polyethylene glycol. The gelatin shell contains FD&C Yellow No. 6 Aluminum Lake, gelatin, glycerin, iron oxide black, lecithin, medium-chain triglycerides, shellac, sorbitol and titanium dioxide.
The invention discloses a medicine used for treating chronic enteritis, which belongs to a field of traditional Chinese medicine.The medicine for treating chronic enteritis is formulated by dangshen, atractylodes macrocephala, povia, chiretta, Szechwan lovage rhizome, red peony root, rhizoma corydalis, cyathula root, salvia root, dioscorea root, cornus dogwood fruit and cassia bark by certain weight. The crude drug is put into an earthenware pot and is soaked by adding proper water; the earthenware pot is firstly decocted to boil by strong fire, and then decocted by aoft fire for half an hour. The liquid medicine is filtered, and proper water is added into dregs and decocted for half an hour; then the medicine liquid is filtered again. Liquid medicine obtained from the two steps is mixed together and cooled. The medicine is taken half an hour before breakfast and two hours after supper respectively.By taking the medicine for half a month, the medicine can clear heat and toxic material, promote digestion, remove food retention and flatulence, alleviate pain, harmonize intestine-stomach, elevate the spleen yang, eliminate dampness and tonify spleen for nourishing qi. By taking the medicine for a month, gastrointestinal disfunction is improved, regeneration and repair of intestinal mucosa is promoted and overall immunity is enhanced, which achieves the goal of complete cure. The invention treat 120 cases all together with a efficient rate of 100 percent and a recovery rate of 99 percent.
Vitamin D insufficiency has recently emerged as a risk factor for susceptibility to multiple sclerosis (MS). The investigator's observational data suggest that lower vitamin D levels in patients with relapsing-remitting MS are associated with a higher subsequent relapse rate. However, it is unknown if providing vitamin D supplementation to such patients leads to a reduction in the risk of an exacerbation. Historically, several nutritional supplements that appeared to be helpful in observational studies of various diseases did not demonstrate a benefit or were harmful in randomized trials. Further, a vitamin D response element was recently identified in the promoter region of Human Leukocyte Antigen (HLA)-DRB1\*15, the gene believed to be critical to initiating the autoimmune response in MS, and 1, 25-dihydroxyvitamin D3 increases the expression of the gene in vitro, suggesting that vitamin D supplementation could even be harmful in established MS.

This is a randomized, double-blind trial of high- versus low-dose vitamin D3 supplementation as an add-on to glatiramer acetate in 172 patients with relapsing-remitting MS. Subjects will be randomized to 600 IU or 5000 IU of oral vitamin D3 daily for two years. A standardized brain MRI scan will be performed at baseline and at the end of the first and second years. The impact of high-dose vitamin D supplementation on the number of relapses, the number of new lesions on brain MRI, and the change in brain volume will be assessed. Establishing these associations will have major implications for the treatment of patients with MS throughout the world and will provide rationale for further investigations of the role of vitamin D in the immunopathogenesis of MS, possibly leading to the identification of new therapeutic targets.
The esophageal pressure (Pes) is used as a surrogate for pleural pressure to obtain transpulmonary pressure. Catheter with air balloon is the most commonly used method to measure the Pes. The optimal injected volume of the balloon is the key factor in accurate measurement of Pes. The recoil pressure of the balloon turns up while the balloon is over-filled, resulting in over-estimation of the PES; on the other hand, an under-filled balloon also cannot properly transmit the surrounding pressure of balloon. However, the researchers showed the optimal balloon volumes is related to the surrounding pressure and even is not correspond with manufacturer's recommendations. Theoretically, when balloon transmural pressure(PTM) is zero, representing the balloon in a condition with equivalent pressure inside and outside of the balloon, it was defined as optimal volume. However, in clinical settings, it is difficult to determine the balloon PTM, and therefore the optimal volume cannot be obtained, because the surrounding pressure of the balloon cannot be conveniently measured.

In the present study, the investigators will develop a simple method to obtain the optimal balloon volume and observe the effect of positive end-expiratory pressure on optimal balloon volume during esophageal pressure monitoring. The investigators want to validate the accuracy of method in the bench study and clinical feasibility in mechanical ventilated patients.
In oncogenicity studies, oxaprozin administration for 2 years was associated with the exacerbation of liver neoplasms (hepatic adenomas and carcinomas) in male CD mice, but not in female CD mice or rats. The significance of this species-specific finding to man is unknown.

Oxaprozin did not display mutagenic potential. Results from the Ames test, forward mutation in yeast and Chinese hamster ovary (CHO) cells, DNA repair testing in CHO cells, micronucleus testing in mouse bone marrow, chromosomal aberration testing in human lymphocytes, and cell transformation testing in mouse fibroblast all showed no evidence of genetic toxicity or cell-transforming ability.

Oxaprozin administration was not associated with impairment of fertility in male and female rats at oral doses up to 200 mg/kg/day (1180 mg/m2); the usual human dose is 17 mg/kg/day (629 mg/m2). However, testicular degeneration was observed in beagle dogs treated with 37.5 to 150 mg/kg/day (750 to 3000 mg/m2) of oxaprozin for 6 months, or 37.5 mg/kg/day for 42 days, a finding not confirmed in other species. The clinical relevance of this finding is not known.
Each patient will be treated for one session of dialysis after enrolled. Each of them will have only one treatment in the middle of the week (Wednesday or Thursday). The patients will be treated using 4008A dialysis machines in combination with a sidecar and the convergence dialyzer as investigational devices.Each patient will be treated according their regular treatment and laboratory analysis will be taken. The blood level of free hemoglobin ( fHb ) will be taken on 30 min by use of HemoCue device. ACT time will be measured on 15 min and for that 0.5 ml blood from venous line will be taken.
PURPOSE:To provide the subject new compounds having an antiallergic effect and an antiasthmatic effect and useful as an antiallergic drug. CONSTITUTION:Compounds of formula I (A-B is =C=CH-or N; R<1> is H, a 1 to 6C alkyl, an aryl or an aralkyl; Z is a 3 to 7C alkylene) and pharmaceutically permissible salts thereof, e.g. (R)-2,2-dimethyl-4-(1,2,3,4,10,14b-hexahydrobenzo[c, f]pyrazino[1,2-a]azepin-2-yl)-butyric acid ethyl ester. The above-mentioned compound can be obtained by reacting a compound of formula II with a halogenated compound of formula III (X is a halogen) in the presence of a base in an inert solvent. The above-mentioned compound exhibits an antihistaminic effect, an antiallergic effect and an antiasthmatic effect. This compound is also excellent in durability, low in side effects such as sleepiness, awakening and excitation and useful as a medicine for preventing and improving allergic diseases or asthma.
PURPOSE:To obtain affinophore useful for separation or purification of wide variety of materials by boding an affinity ligand to a free basic group or free COOH group in the side chain of a water-soluble polyamino acid. CONSTITUTION:An affinophore is prepd. by bonding an affinity ligand (e.g., amino acid, peptide, etc.) to a free basic group or free COOH group of a water- soluble polyamino acid (e.g., lysine, arginine, etc.) having a positive or negative charge in the side chain, pref. 10,000-50,000mol.wt. and free basic group in the side chain, or to a water-soluble polyamino acid (e.g., glutaminic acid, aspartic acid, etc.) having free COOH group in the side chain. The amide bonding may be performed using or without using an appropriate joint group. Further, the rate of introducing the affinity ligand is 1-30wt% for the affinity ligand having <=300mol.wt., and ca. 30-300wt% for high molecular compds. having >=10,000mol.wt.
TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.
OBJECTIVES: Cerebral venous sinus thrombosis (CVST) is a rare but serious manifestation of venous thrombosis in patients with antiphospholipid syndrome (APS). This study investigated the risk factors, clinical characteristics and prognosis of CVST in APS patients.
METHODS: This retrospective cohort study included all thrombotic APS (tAPS) patients from Peking Union Medical College Hospital (PUMCH) from April 2005 to August 2023. Demographic characteristics, laboratory data and thrombotic risk factors were compared between tAPS-CVST group and tAPS-non-CVST group. Kaplan-Meier survival analysis was utilized to compare the recanalization rate and the recurrence rate.
RESULTS: A total of 453 APS patients were enrolled, and 40 (8.8%) APS patients were with CVST. The median age of the APS-CVST patients was 27 (21.25, 32.75) years, and 72.5% were females. In 50% of these patients, CVST was the initial symptom of APS, with headache being the most prevalent clinical symptom (95%). Involvement of more than two venous sinuses were observed in 79.5% of patients, with the transverse sinus (79.5%) and sigmoid sinus (74.4%) being the most commonly affected sites. Oral contraceptives, intracranial infections and malignancy were identified as risk factors of APS-CVST. There were no statistically significant differences in baseline characteristics or the distribution of antiphospholipid antibodies profiles between the two groups. After a median follow-up of 24 (12, 52) months, 21 patients (52.5%) experienced recanalization, and 13 patients (32.5%) had a thrombotic recurrence. Survival analysis indicated that adequate anticoagulant therapy significantly contributed to recanalization (HR 6.27, 95% CI 2.616-15.02, P = 0.003), while continuous anticoagulant therapy was highly effective in reducing the recurrence of thrombotic events (HR 0.14, 95% CI 0.0447-0.4328, P = 0.0007).
CONCLUSION: CVST should be considered in APS patients who experience sudden onset headaches, particularly those with thrombotic risk factors, such as the use of oral contraceptives, intracranial infections and malignancy. Continuous and adequate anticoagulant therapy is pivotal and beneficial for achieving recanalization and prevention of recurrence. Key Points • The prevalence of CVST in patients with APS may be underestimated. • APS-CVST is associated with special risk factors, including pregnancy, intracranial infection, oral contraceptives and tumors. • Long-term and adequate anticoagulation therapy can increase the vascular recanalization rate and reduce thrombosis recurrence.
There are three main research tasks for this project: 1) the identification of discriminant features of Doppler audio for patient classification, 2) the selection and training of classification algorithms, and 3) CWD audio data enrichment using physics-based models. The investigators will determine which discriminant features are optimal for patient classification from ultrasound Doppler audio.

To this end, the investigators will employ signal features in the frequency domain such as bandwidth, peak frequency, mean power, mean frequency, and time harmonic distortion, among others.

Furthermore, the investigators will investigate whether time domain features are necessary for accurate sound classification. Other studies have shown that specific features of audio waveforms can classify the data. The investigators will employ some of the most effective machine-learning algorithms for classification such as SVM, logistic regression, and Naïve Bayes, among others. The investigators will start with a binary classification problem in which individuals will be classified as healthy or unhealthy. Then, the investigators will move in complexity to multi-class classification problems in which individuals will be categorized into different groups according to defined abnormal arterial conditions. Data enrichment using physics-based models employing physiologically accurate finite element models of fluid flow in arteries to generate synthetic sound signals corresponding to various arterial conditions. Physics-based simulations would allow the investigators to produce a wealth of training data that can span many known arterial conditions. This capability can augment the classification accuracy and generalization of our algorithms, as clinical data may not be exhaustive enough to incorporate all the known arterial conditions. The investigators will study the performance of the trained algorithms on patient data. To this end, the investigators will partition the data into training and testing samples. The training samples will be used for training of the algorithms, while the testing set will be used to assess generalization capability. The investigators will compute misclassification rates for each algorithm as a metric for performance.
Subjects who have previously or are currently being evaluated for progressive cognitive decline. Enrolling physicians must have a confidence of less than 85% in their initial diagnosis of the subject's progressive cognitive decline and that there was at least a 15% chance that the subject's progressive cognitive decline was due to Alzheimer's disease. All subjects who did not complete the study withdrew before receiving a florbetapir F 18 injection and PET scan.
Daily experiences of mothers caring for children with Prader-Willi syndrome (PWS) are largely unknown and unvoiced. Knowledge of PWS has generally focused on pathology of the disorder. This emphasis overlooks the challenging moments of everyday life caring for children with PWS. Storied accounts of mothers caring for children with PWS offer expanded narratives to medicalized descriptions of experience. An understanding of everyday challenges in managing physical and mental health issues of PWS including hyperphagia and anxiety may create shifts in social and clinical perspectives. This understanding could improve practices in health and social care for families with PWS. This narrative inquiry studied everyday experience using storied accounts. Participants were mothers caring for children aged 3-17 years with genetically confirmed PWS who were experiencing hyperphagia. Four participants were recruited, and each interviewed 8-12 times over 12 months. Field texts and narrative accounts were co-composed through a collaborative process of analysis. Engaging with participants' day-to-day experiences offered insights into their work of nurturing, caring, and contributing to the care of a child with PWS. Narrative threads focused on complexity and rarity and include the desire to be normal, how ordinary becomes extraordinary, isolation, behaviors and normative standards, and alternative stories of mothering. Recommendations for practice and policy include (a) challenges of mothering a child with complexity, (b) moving beyond functionality and impairment to participation and quality of life, (c) re-storying narratives and supports for families, and (d) engaging with mothers to determine care priorities.
FIELD: biotechnology. SUBSTANCE: liposomal vesicle with lipid envelope consisting of lecithin and cholesterol and can be used in medicine, in part, in pharmacology. Lipid envelope of vesicle has additionally a mixture of acid phospholipids. Indicated mixture is isolated as a united negatively charged phospholipid component from soybean phosphatides. Vesicle has additionally incapsulated cytochrome c taken at ratio to lipid envelope (mas. p. p.) = 1:(6-8). Lipid envelope of vesicle can has additionally tocopherol taken at amount 1.1-2.2% of total lipid envelope mass. EFFECT: enhanced therapeutic effectiveness and prolonged effect as compared with native form of cytochrome c. 3 tbl
An intranasal injection of 8 mL epinephrine 1:100,000 will be performed as traditionally practiced in ESS. Thereafter, cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
FIELD: medicine. SUBSTANCE: proposed preparation is prepared of protosubtiline with the help of ion-exchange chromatography on carboxymethyl cellulose. It is white powder being soluble in water and in isotonic solution of sodium chloride. Solutions of said preparation have high stability at pH 7.0-8.0 and 5-10 C. Optimal conditions for using preparation are: 50 C, pH 7.0-7.5. Proteolytic activity of preparation at 37 C is 3.5-4.2 proteolytic units per 21 kg of protein. Proposed preparation may be used subconjunctively, as instillations, with the help of electrophoresis and photophoresis. EFFECT: increases activity of preparation. 3 tbl
This will be Randomized clinical trial. Individuals who met inclusion criteria will be included in this study. All participants will go through randomization and divided into two groups. Pre intervention assessment is made for both groups. Then intervention will apply to both groups. Group A will receive positional release technique and Group B will be treated by manual pressure technique and pain, range of motion, lumbosacral angle and functional disability will be measured before and after the treatment using NPRS, Inclinometer and ODI. Estimated time of treatment protocol will be 30 minutes per session, 4 times/week for 4 weeks in the hospital setting. Subjects will be evaluated at baseline and 4th week assessment will be the final.